SS-OCT, SS-OCTA provide useful findings in active ocular toxoplasmosis


These imaging technologies can help with assessing unexpected structural and vascular retinal and choroidal changes in active and post-treatment toxoplasmic retinochoroiditis.

SS-OCT, SS-OCTA for ocular toxoplasmosis

This article was reviewed by João Rafael de Oliveira Dias, MD, PhD

Swept-source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA) are helpful in clinical practice to assess patients with active toxoplasmic retinochoroiditis. OCTA, especially, may be helpful toward visualizing some unique features of ocular toxoplasmosis in clinical practice, said João Rafael de Oliveira Dias, MD, PhD.

Toxoplasmosis—the most common cause of intraocular inflammation and posterior uveitis in immunocompetent patient—results from ingestion of raw or undercooked meat infested with Toxoplasma gondii and water or food containing oocysts excreted by cats with the infection. The infection is dangerous and can result in abortion and death of a fetus in the congenital form of the disease and neurocognitive deficits and retinochoroiditis in neonates. Acquired toxoplasmosis can result in ocular lesions in up to 20% of patients with the infection, according to previous studies.

The authors studied 15 patients (15 eyes; 9 females; mean age, 32.4 years) who presented with active toxoplasmic retinochoroiditis. All patients underwent imaging with SS-OCT and SS-OCTA (DRI OCT Triton, Topcon) before and after treatment and underwent serologic and clinical assessments to confirm toxoplasmosis infection, and to rule out syphilis and HIV. All patients had positive anti-T. gondi immunoglobulin G titers and 3 also had positive anti-T. gondi immunoglobulin M titers, de Oliveira Dias noted.

“SS-OCT combined with en face and OCTA technologies is a non-invasive imaging technology that is particularly useful for assessing patients with active ocular toxoplasmosis, because it allows visualization of the vitreous and all retinal layers up to the choroid. Despite the presence of vitritis, this approach also provides better images compared with spectral-domain [SD] and time-domain OCTs. …We believe that SS-OCT and SS-OCTA proved better information in comparison to SD-OCT and SD-OCTA, as previous reports have shown that SS-OCT has less sensitivity roll-out and better visualization through media opacities when compared to SD-OCT,” the study investigators commented.

They published their findings in the International Journal of Retina and Vitreous.1

SS-OCT B-scan ocular findings

SS-OCT showed classic presumed toxoplasmic focal fundus lesions in all eyes, and in 33% an adjacent retinal choroidal scar. Before treatment, punctate hyperreflective spots, i.e., inflammatory material and inflammatory cells, were seen in the posterior vitreous. Following treatment, fewer vitreous cells were seen. Four eyes had preretinal oval deposits over areas of retinitis.

The authors also reported the presence of increased retinal reflectivity and thickness in all eyes before treatment that was associated with disorganization of the neuroretinal layer boundaries at the active lesion sites; 20% of eyes had perilesional subretinal fluid.

Other observations were focal choroidal thickening beneath the area of retinitis in 80% of eyes, and all eyes had a choroidal hyporeflective signal. Following treatment, a retinal choroidal scar was seen with a disrupted, thinning choroid beneath a thin hyperreflective retina, and the disorganized retinal layer reflectivity resulting from scar formation remained in all eyes, the investigators reported.

SS-OCTA observations

OCTA showed no decorrelation signal, which suggested reduced blood flow, according to Oliveira Dias. “After healing,” he commented, “OCTA images showed persistent reduced flow signal in 11 patients with partial regression of the previously observed hyporeflective signal and improved visualization of the normal architecture of the vascular retinal layers. The superficial and deep retinal capillary plexuses and the choriocapillaris could have been affected by the disorganization of the neurosensory retina due to toxoplasmosis retinochoroiditis.”

Retinal neovascularization was seen in 1 patient at baseline, which remained unchanged after T. gondii treatment. This patient underwent sectorial retinal photocoagulation at the follow-up visit. Another patient was diagnosed with a presumed subclinical choroidal neovascular membrane following 6 weeks of treatment of the active ocular toxoplasmosis. Three patients presented with intraretinal vascular abnormalities after treatment that were seen on the OCTA images.

Imaging advantages

The authors commented, “The current study is the largest investigation to date of patients with active ocular toxoplasmosis that underwent SS-OCTA at baseline and during follow-up. Three patients had a primary systemic toxoplasmosis infection and showed positive anti-Toxoplasma IgM titers. We also reported for the first time the unique features of ocular toxoplasmosis seen in the OCTA images, including retinal neovascularization and a lesion that was presumed to be a subclinical choroidal neovascular membrane in an eye with active ocular toxoplasmosis.”

They explained that while retinal neovascularization has been reported previously in patients with ocular toxoplasmosis, OCTA was valuable in this patient because “the retinal new vessels were not promptly recognized during routine indirect ophthalmoscopy. In addition, fluorescein angiography is not performed routinely in patients with ocular toxoplasmosis because of the risk of adverse events, inconvenience, and discomfort associated.”

The investigators concluded thatSS-OCT and SS-OCTA are useful for assessing unexpected structural and vascular retinal and choroidal changes in active and post-treatment toxoplasmic retinochoroiditis, which are useful for clinical practice.

João Rafael de Oliveira Dias, MD


de Oliveira Dias, MD, is from the Department of Ophthalmology, Federal University of São Paulo, Paulista Medical School, and the Vision Institute, São Paulo, SP, Brazil. de Oliveira Dias has no financial interest in this subject matter.


1. de Oliveira Dias J, CampeloC, Novais EA, et al. Int J Retin Vitr (2020; 6:30

Related Videos
Video 4 - "Treating Geographic Atrophy in Patients with Concurrent Neovascular AMD"
Video 3 - "Managing a Patient with Bilateral Geographic Atrophy"
Video 2 - "FDA-approved Therapies for Geographic Atrophy"
Video 1 - "Geographic Atrophy: Overview, Diagnosis, and Progression"
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2024 MJH Life Sciences

All rights reserved.